Lanfos 250 mg Chewable Tablet
Lanfos 250 mg Chewable Tablet Uses, Dosage, Side Effects, Food Interaction and all others data.
Lanfos 250 mg Chewable Tablet is a phosphate binder commonly used in clinical practice. It is marketed under the trade name Fosrenol by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led to severe choking. It is prescribed for treating high phosphate levels, mainly found in patients with chronic kidney disease. Lanthanum should be taken with meals and binds to phosphate in the diet, preventing phosphate absorption in the intestine.
In vitro studies have shown that lanthanum binds phosphate in the physiologically relevant pH range of 3 to 7. In simulated gastric fluid, lanthanum binds approximately 97% of the available phosphate at pH 3-5 and 67% at pH 7, when lanthanum is present in a two-fold molar excess to phosphate. Bile acids have not been shown to affect the phosphate binding affinity of lanthanum. In order to bind dietary phosphate, lanthanum carbonate must be administered with or immediately after meals.
| Trade Name | Lanfos 250 mg Chewable Tablet |
| Generic | Lanthanum carbonate |
| Lanthanum carbonate Other Names | Lanthanum (III) carbonate, Lanthanum sesquicarbonate, Lanthanum(3+) carbonate |
| Weight | 250 mg |
| Type | Chewable Tablet |
| Formula | C3La2O9 |
| Weight | Average: 457.835 Monoisotopic: 457.76695 |
| Protein binding | In vitro, lanthanum is highly bound (>99%) to human plasma proteins, including human serum albumin, α1-acid glycoprotein, and transferrin. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | Beacon Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | September 24, 2024 at 5:38 am |
Uses
Lanfos 250 mg Chewable Tablet is a phosphate binder indicated for the reduction of serum phosphate in patients with end stage renal disease.
Used to reduce serum phosphate in patients with end stage renal disease (ESRD).
Lanfos 250 mg Chewable Tablet is also used to associated treatment for these conditions: Hyperphosphataemia
How Lanfos 250 mg Chewable Tablet works
Lanfos 250 mg Chewable Tablet is a phosphate binder that reduces absorption of phosphate by forming insoluble lanthanum phosphate complexes that pass through the gastrointestinal (GI) tract unabsorbed. Both serum phosphate and calcium phosphate product are reduced as a consequence of the reduced dietary phosphate absorption.
Toxicity
The symptoms associated with overdose are adverse reactions such as headache, nausea and vomiting. Lanfos 250 mg Chewable Tablet was not acutely toxic in animals by the oral route. No deaths and no adverse effects occurred in mice, rats or dogs after single oral doses of 2000 mg/kg.
Food Interaction
- Take with food.
Elimination Route
Bioavailability very low (<0.002%) following single or multiple dose oral administration.
Half Life
Elimination half-life of 53 hours.
Clearance
In healthy volunteers administered intravenous lanthanum as the soluble chloride salt (120 μg), renal clearance was less than 2% of total plasma clearance.
Elimination Route
No information is available regarding the mass balance of lanthanum in humans after oral administration. In rats and dogs, the mean recovery of lanthanum after an oral dose was about 99% and 94%, respectively, and was essentially all from feces. Biliary excretion is the predominant route of elimination for circulating lanthanum in rats.
Innovators Monograph
You find simplified version here Lanfos 250 mg Chewable Tablet
